Pharmacokinetic interactions between theophylline and rioprostil.
The study is of double-blind crossover design. The effects of rioprostil, an analogue of prostaglandin E1, at a dose of 300 micrograms b.d., and placebo on the kinetic of slow-release theophylline are investigated. Eight healthy male volunteers participate in the study, each study period lasting for one week. During the first period, the doses of theophylline are altered in response to measured theophylline levels, 200 mg or 400 mg b.d. Regardless of placebo or rioprostil treatment, side effects appear before day 6 and are related specifically to theophylline administration. Blood samples are taken on days 4 and 5 to check steady-state plasma levels of theophylline and on days 6 and 7 to determine the main pharmacokinetic parameters. The same schedule is used for the second period of treatment. The achievement of steady-state concentration is verified. The mean pharmacokinetic parameters do not show a significant difference when slow-release theophylline is given alone or with rioprostil. These results are likely to be clinically relevant and, therefore, the theophylline dose should not be changed if rioprostil is prescribed at the same time as the theophylline.
de Lauture
D
D
Département de Pharmacologie Clinique, Hôpital Saint-Vincent de Paul, Paris, France.
Rey
E
E
d'Athis
P
P
Richard
M O
MO
Paccaly
D
D
Prunieras
F
F
Strauch
G
G
Olive
G
G
D000328:Adult; D000897:Anti-Ulcer Agents / Q000493:pharmacokinetics* / Q000494:pharmacology; D004311:Double-Blind Method; D004347:Drug Interactions; D006801:Humans; D008297:Male; D010865:Pilot Projects; D011458:Prostaglandins E / Q000493:pharmacokinetics* / Q000494:pharmacology; D011465:Prostaglandins, Synthetic / Q000493:pharmacokinetics / Q000494:pharmacology; D016630:Rioprostil; D013806:Theophylline / Q000493:pharmacokinetics* / Q000494:pharmacology
D000897:Anti-Ulcer Agents; D011458:Prostaglandins E; D011465:Prostaglandins, Synthetic; D016630:Rioprostil; D013806:Theophylline